Invesco’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-81,035
| Closed | -$808K | – | 3822 |
|
|
2025
Q2 | $808K | Sell |
81,035
-4,167
| -5% | -$33.6K | ﹤0.01% | 2940 |
|
|
2025
Q1 | $509K | Buy |
85,202
+762
| +0.9% | +$5.59K | ﹤0.01% | 3145 |
|
|
2024
Q4 | $648K | Buy |
84,440
+85
| +0.1% | +$730 | ﹤0.01% | 3122 |
|
|
2024
Q3 | $861K | Sell |
84,355
-231
| -0.3% | -$3.52K | ﹤0.01% | 2976 |
|
|
2024
Q2 | $1.26M | Buy |
84,586
+27
| +0% | +$387 | ﹤0.01% | 2813 |
|
|
2024
Q1 | $1.15M | Buy |
84,559
+47,526
| +128% | +$518K | ﹤0.01% | 2933 |
|
|
2023
Q4 | $406K | Sell |
37,033
-170,132
| -82% | -$1.69M | ﹤0.01% | 3323 |
|
|
2023
Q3 | $2.27M | Sell |
207,165
-8,202
| -4% | -$105K | ﹤0.01% | 2555 |
|
|
2023
Q2 | $2.85M | Sell |
215,367
-373,194
| -63% | -$5.32M | ﹤0.01% | 2510 |
|
|
2023
Q1 | $8.01M | Sell |
588,561
-20,039
| -3% | -$359K | ﹤0.01% | 1968 |
|
|
2022
Q4 | $11.9M | Buy |
608,600
+63,421
| +12% | +$1.24M | ﹤0.01% | 1731 |
|
|
2022
Q3 | $10.4M | Buy |
545,179
+38,549
| +8% | +$888K | ﹤0.01% | 1772 |
|
|
2022
Q2 | $10.4M | Buy |
506,630
+381,607
| +305% | +$9.06M | ﹤0.01% | 1822 |
|
|
2022
Q1 | $4.02M | Buy |
125,023
+78,056
| +166% | +$2.84M | ﹤0.01% | 2478 |
|
|
2021
Q4 | $2.19M | Buy |
46,967
+39,223
| +506% | +$1.31M | ﹤0.01% | 2762 |
|
|
2021
Q3 | $209K | Buy |
+7,744
| New | +$202K | ﹤0.01% | 3784 |
|
Other funds holding ITOS
Invesco's ITOS Position: Q3 2025 in Review
Invesco sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 81,035 shares — an estimated $808K sold.
Invesco first reported a position in ITOS in Q3 2021 and held it in 16 quarters. The position peaked at $11.9M in Q4 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Invesco reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Invesco sold 81,035 iTeos Therapeutics shares in Q3 2025, an estimated $808K.
- Invesco first reported a position in iTeos Therapeutics in Q3 2021 and held it in 16 quarters.
- Invesco's iTeos Therapeutics position peaked at $11.9M in Q4 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Invesco's 13F filing for Q3 2025, filed 13 Nov 2025.